When evaluated both clinically and histologically at day 7, treatment with anti-IL-17A antibody improved the dermatitis in both PD-1−/− and WT mice to a level equivalent to treatment with anti-IL-6R antibody (Supplemental Fig. 5A–E). This evidence concerns the gene IL17A and skin disorder.